Oxcia AB (publ) today reports that three abstracts on OXC-101, its clinical candidate for cancer, have been selected for poster presentations at the American Association for Cancer Research (AACRS) Annual meeting held in Orlando, Florida, 14-19[th] April, 2023 . The abstracts concern the clinical safety, further understanding of the broad anti-cancer efficacy and the mechanism of action and will be published in the online Proceedings supplement of the AACR journal Cancer Research.
Many cancers suffer from oxidative stress and high levels of endogenous oxidative DNA damage. The enzyme MTH1 protects cancer cells from oxidative DNA damage by preventing incorporation of oxidized DNA base pairs. OXC-101 is a dual-action mitotic disruptor and MTH1 inhibitor, i.e. a mitotic MTH1 inhibitor, stopping cancer cells from dividing, causing more oxidative stress and oxidative DNA damage, thereby killing cancer cells. It effectively takes advantage of the high level of oxidative DNA damage in cancer cells.
The first abstract summarizes the report on the favorable safety profile of OXC-101 in the MASTIFF (MTH1, A Phase I, Study on Tumors Inhibition, First-in-Human, First in Class) study (Title: : OXC-101 shows favorable safety profile in first-in-human phase 1 trial in patients with advanced solid cancer. Authors: Jeffrey Yachnin, Lars Ny, Teresa Sandvall, Kumar Sanjiv, Martin Scobie, Björn Platzack, Pawel Baranczewski, Olof Breuer, Vassilis Gorgoulis, Ioannis S Pateras, Maria Klockare, Austin Smith, Ulrika Warpman Berglund, Thomas Helleday). MASTIFF is a first- in- human phase 1 study, with the primary aim to assess safety, tolerability, and pharmacokinetics of OXC-101 in patients with advanced solid malignant tumors. All patients had progressive, stage 4 disease with palliative care or participations in clinical trials as only treatment options. The AACR poster presentation takes place Tuesday April 18th,2023, 9.00am-12.30pm. The abstract (Number CT182) will be published online in Proceedings supplement to the AACR journal Cancer Research Friday April 14th , 2023.
The second abstract is related to the further understanding of the underlying mechanism of action of OXC-101 and the broad and cancer specific effects in solid cancers. (Title: OXC-101 kills cancer by disturbing microtubule polymerization and inhibiting MTH1. Authors: Ulrika Warpman Berglund, Helge Gad, Ann-Sofie Jemth, Oliver Mortusewitz, Lars Brautigam, Kumar Sanjiv, Juha Rantala, Thomas Helleday). The AACR poster presentation takes place Monday April 17th ,, 2023, 9.00am-12.30pm. The abstract (Number 1569) will be published online in Proceedings supplement to AACR journal Cancer Research Friday, March 31st, 2023.
The third presentation supports the proposed mechanism of action of OXC-101 and demonstrates an enhanced efficacy of OXC-101 in combination with other compounds that stop cancer cell cycle progression and DNA repair, such as DNA-PK inhibitors (Title:DNA-PK inhibition augment the cancer specific cytotoxicity of MTH1 inhibitor and microtubule poisons. Authors: Akhilesh Nagesh Danda, Helge Gad, Martin Scobie, Thomas Helleday, Ulrika Warpman Berglund, Kumar Sanjiv). The AACR poster presentation takes place Wednesday April 19, 2023, 9.00am-12.30pm. The abstract (Number 6204) will be published online in Proceedings supplement to AACR journal Cancer Research Friday, March 31s, 2023.
“We are thrilled to be presenting OXC-101 clinical first-in-human safety data as well as new preclinical data supporting the unique dual mechanism of OXC-101 and broad anti-cancer efficacy at the AACR Annual meeting, one of the biggest conferences for cancer research.” says Ulrika Warpman Berglund, CEO at Oxcia.
För ytterligare information kontakta:
Ulrika Warpman Berglund, VD, Oxcia AB (publ)
Telefon: +46 (0) 73 270 9605
Briefly about Oxcia
Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR – the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two DDR drug candidates, both with the potential to become first-in-class drugs. OXC-101 is in early clinical development as novel cancer therapy. OXC-201 is developed against inflammatory and fibrosis-related diseases, such as pulmonary fibrosis and allergic asthma, and is in the preclinical phase.
More information about Oxcia is available at www.oxcia.com